International Stem Cell (ISCO) Total Liabilities (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Total Liabilities of $4.6 million for Q4 2025, down 4.66% year-over-year from $4.8 million in Q4 2024, and down 3.76% quarter-over-quarter from $4.8 million in Q3 2025.
International Stem Cell (ISCO) Total Liabilities (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Total Liabilities for 16 consecutive years, with $4.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities fell 4.66% year-over-year to $4.6 million; the TTM figure through Dec 2025 stood at $4.6 million (down 4.66% YoY), while the FY2025 annual figure was $4.6 million, down 4.66% from the prior year.
- Total Liabilities slipped to $4.6 million in Q4 2025 per ISCO's latest filing, from $4.8 million in the prior quarter.
- Across five years, Total Liabilities topped out at $6.4 million in Q1 2021 and bottomed at $4.6 million in Q4 2025.
- Historically, Total Liabilities has averaged $5.3 million across 5 years, with a median of $5.3 million in 2023.
- Annual changes were most pronounced in 2021 — Total Liabilities advanced 18.42% — and 2022, when it slipped 11.06%.
- International Stem Cell's Total Liabilities stood at $5.2 million in 2021, then climbed by 2.31% to $5.4 million in 2022, then slipped by 1.46% to $5.3 million in 2023, then declined by 8.98% to $4.8 million in 2024, then retreated by 4.66% to $4.6 million in 2025.
- Business Quant data shows ISCO's Total Liabilities at $4.6 million in Q4 2025, $4.8 million in Q3 2025, and $5.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 4.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.98 Mn |
| Dec 31, 2025 | 4.58 Mn |
| Sep 30, 2025 | 4.76 Mn |
| Jun 30, 2025 | 5.14 Mn |
| Mar 31, 2025 | 5.41 Mn |
| Dec 31, 2024 | 4.80 Mn |
| Sep 30, 2024 | 4.92 Mn |
| Jun 30, 2024 | 5.31 Mn |
| Mar 31, 2024 | 5.33 Mn |
| Dec 31, 2023 | 5.28 Mn |
| Sep 30, 2023 | 5.20 Mn |
| Jun 30, 2023 | 5.33 Mn |
| Mar 31, 2023 | 5.49 Mn |
| Dec 31, 2022 | 5.36 Mn |
| Sep 30, 2022 | 5.39 Mn |
| Jun 30, 2022 | 5.53 Mn |
| Mar 31, 2022 | 5.71 Mn |
| Dec 31, 2021 | 5.23 Mn |
| Sep 30, 2021 | 4.99 Mn |
| Jun 30, 2021 | 5.62 Mn |